Videos
June 10, 2021
Briana Choi, PharmD, discusses results from a study evaluating the cost-effectiveness of adjunctive maintenance therapy with osimertinib in resected EGFR-positive NSCLC, finding that it varies across stages of disease.
Conference Coverage
June 10, 2021
Rituximab-abbs may have more economic benefits compared to reference rituximab in patients with NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Conference Coverage
June 09, 2021
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
Conference Coverage
June 09, 2021
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
Conference Coverage
June 05, 2021
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
Conference Coverage
June 05, 2021
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
Conference Coverage
June 04, 2021
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
Conference Coverage
June 04, 2021
Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.
Conference Coverage
June 03, 2021
A study exploring practice patterns in HER2-positive breast cancer in the United States found that the most common second-line treatment following first-line pertuzumab plus trastuzumab were T-DM1-based regimens.
Conference Coverage
June 03, 2021
Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world PFS compared with those who receive fulvestrant alone.
Conference Coverage
June 03, 2021
Neoadjuvant pertuzumab, trastuzumab, and hyaluronidase-zzxf plus chemotherapy is expected to be cost-effective vs neoadjuvant pertuzumab and trastuzumab plus chemotherapy for patients with high-risk HER2-positive early breast cancer.
Videos
July 29, 2020
Richard Penson, MD, MRCP, discusses the results from the SOLO2 study assessing maintenance olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Videos
July 09, 2019
The third installment of the roundtable panel at the ASCO Annual Meeting dissects a current value-based agreement for a TKI therapy for renal cell carcinoma in the UK and potential applicability in the US.
Videos
July 02, 2019
The second installment of the roundtable panel at the ASCO Annual Meeting explores a current value-based agreement for CAR-T therapy in Germany and potential applicability in the US.
Videos
June 25, 2019
A roundtable discussion at the ASCO Annual Meeting featured payer, provider, and manufacturer perspectives on the viability of value-based agreements in the US oncology space today.
News
June 20, 2019
Women with ovarian cancer may be more willing to accept the side effects of PARP inhibitor maintenance therapy in exchange for improved PFS, according to a recent study.
Interviews
June 20, 2019
Adil Akhtar, MD, Michigan Health Professionals, and Charles Saunders, MD, Integra Connect, dissect the cost implications and quality improvement opportunity of a palliative care program at a large OCM community practice, along with the “cultural change” surrounding palliative care in oncology.
News
June 17, 2019
A study presented at the ASCO Annual Meeting shed light on a treatment approach that led to improved objective response rates in patients with platinum-sensitive, relapsed ovarian cancer.
News
June 14, 2019
A national patient advocacy survey explored the extent of patient-reported disease burden in multiple hematologic malignancies.
News
June 13, 2019
The majority of FDA-approved checkpoint inhibitors demonstrate a significant benefit in the palliative care setting for patients with cancer, according to ASCO and ESMO value frameworks.
News
June 05, 2019
Authors presenting performance results of a palliative care program in a large community oncology practice explained how their program was able to lower costs for patients and improve OCM performance.
News
June 05, 2019
Bianca D Santomasso, MD, PhD, spoke at length at the ASCO Annual Meeting about the clinical manifestations of neurotoxicity, the neurotoxicity correlations underlying why it happens, and new grading guidelines for management.
News
June 02, 2019
A session at the ASCO Annual Meeting delved into the most common adverse effects of CAR T-cell therapy, including cytokine release syndrome and neurologic toxicity, along with independent predictors of each.
News
June 02, 2019
ASCO and ESMO value frameworks may require additional refinement in order to accurately capture the benefit of long-term survival with various therapy types, according to a study presented at the ASCO Annual Meeting.
News
June 02, 2019
A presentation at the ASCO Annual Meeting explored the role that the clinical pathways program at the Levine Cancer Institute plays in clinical trial enrollment.
News
June 01, 2019
Changes in physician payments since the inception of the Open Payments program highlight the importance of transparency in policymaking, according to a study presented at the ASCO Annual Meeting.
News
June 01, 2019
Data presented at the ASCO Annual Meeting provide the longest efficacy and safety follow-up results for patients with NSCLC treated with pembrolizumab.
News
May 31, 2019
A session at the ASCO Annual Meeting touched on strategies to building personalized cancer follow-up care pathways in the US, drawing from implementation in England, Northern Ireland, and Australia.
News
May 29, 2019
Patients undergoing CAR-T therapy may not experience a significant decline in quality of life compared with those undergoing autologous or allogeneic stem cell transplant, according to a study to be presented at the ASCO Annual Meeting.
News
May 22, 2019
A study to be presented at the ASCO Annual Meeting found that the incidence of second primary neoplasia in patients treated with BTK inhibitors for CLL is increased relative to the general population.
News
May 16, 2019
A study to be presented at the ASCO Annual Meeting found that improvement in event-free survival in newly diagnosed AML is associated with a significant decrease in health care utilization, regardless of overall survival duration.